A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.

Marc J B DamRasmus Kristoffer Pedersen Trine Alma Knudsen Morten Andersen Christina Ellervik Morten Kranker Larsen Lasse Kjaer Vibe Skov Hans Carl Carl Hasselbalch Johnny T Ottesen

Published in: Cancer medicine (2022)

This novel tool convincingly displays the superiority of IFN versus HU in normalizing elevated cell counts. Our results need to be validated in larger studies but already now call for studies of the safety and efficacy of combination therapy during the initial treatment of patients with MPNs.

Keyphrases

combination therapy
dendritic cells
case control
single cell
immune response
cell therapy
stem cells
peripheral blood